



Form PTO-1449 MAR 21 2008 PATENT & TRADEMARK OFFICE		<b>U.S. Department of Commerce Patent and Trademark Office</b>			<b>Atty. Docket No.</b> 60390-AZ-PCT-US/JPW/GJG/ML		<b>Serial No.</b> 10/816,329	
<b>INFORMATION DISCLOSURE CITATION</b> (Use several sheets if necessary)					<b>Applicants:</b> Arlindo Castelhana et al.		<b>Filing Date</b> March 31, 2004	
<b>U.S. PATENT DOCUMENTS</b>					<b>Group</b>			
Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date if Appropriate		
	1 5 8 8 9 0 2 6	3/30/99	Alanine et al.					
	2 6 1 1 7 8 7 8	9/12/00	Linden					
	3 6 4 6 5 4 5 6	10/15/02	Springer et al.					
	4 6 6 8 0 3 2 2	1/20/04	Castelhano et al.					
	5 6 9 1 6 8 0 4	7/12/05	Castelhano et al.					
	6 7 2 0 2 2 5 2	4/10/07	Wilson et al.					
	7 20 03 01 39 4 2 7	11/1/05	Castelhano et al.					
	8 20 03 02 29 0 6 7	12/11/03	Castelhano et al.					
	9 20 04 00 82 5 9 8	4/29/04	Castelhano et al.					
	10 20 04 00 82 5 9 9	4/29/04	Castelhano et al.					
	11 20 05 01 19 2 7 1	6/2/05	Castelhano et al.					
	12 10 0 1 0 0 9 2	11/30/01	Castelhano et al.					
<b>FOREIGN PATENT DOCUMENTS</b>								
	Document Number	Date	Country	Class	Subclass	Translation		
						Yes	No	
	13 12 4 6 6 2 3 B1	8/9/06	EPO					
	19 20 01 03 9 7 7 7	6/7/01	PCT					
	20 20 02 05 7 2 6 7	7/25/02	PCT					
	21 20 03 04 8 1 2 0	6/12/03	PCT					
	22 20 03 05 3 3 6 1	7/3/03	PCT					
	23 20 03 05 3 3 6 6	7/3/03	PCT					
	24 9 7 4 7 6 0 1	12/18/97	PCT					
	25 9 9 6 4 4 0 7	12/16/99	PCT					
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>								
	14	Hungarian Patent No. HU P9303515 (corresponds to WO 94/13676)						
	15	Hungarian Patent No. HU P9501230 (corresponds to WO 95/19970)						
	16	Hungarian Patent No. HU P9602013 (corresponds to WO 95/19970)						
	17	Hungarian Patent No. HU P9402829 (corresponds to WO 93/20078)						
	18	Hungarian Patent No. HU P9602017 (corresponds to WO 95/19774)						
	26	International Search Report issued in PCT International Application No. PCT/US2001/045280, filed November 30, 2001						
	27	International Search Report issued in PCT International Application No. PCT/US2002/38055, filed November 27, 2002						
	28	International Search Report issued in PCT International Application No. PCT/US2002/40890, filed December 20, 2002						
	29	International Search Report issued in PCT International Application No. PCT/US2002/41273, filed December 20, 2002						
	30	PCT International Preliminary Examination Report issued in PCT International Application No. PCT/US2001/045280, filed November 30, 2001						
	31	PCT International Preliminary Examination Report issued in PCT International Application No. PCT/US2002/38055, filed November 27, 2002						
	32	PCT International Preliminary Examination Report issued in PCT International Application No. PCT/US2002/40890, filed December 20, 2002						
	33	PCT International Preliminary Examination Report issued in PCT International Application No. PCT/US2002/41273, filed December 20, 2002						
EXAMINER			DATE CONSIDERED					
*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.								

Applicants: Arlindo Castelhana et al.  
 Serial No.: 10/816,329  
 Filed: March 31, 2004  
**Exhibit A**

<b>Form PTO-1449</b>		<b>U.S. Department of Commerce Patent and Trademark Office</b>			Atty. Docket No. <b>60390-AZ-PCT-US/JPW/GJG/ML</b>		Serial No. <b>10/816,329</b>	
<b>INFORMATION DISCLOSURE CITATION</b> (Use several sheets if necessary)					Applicants: <b>Arlindo Castelhana et al.</b>			
					Filing Date <b>March 31, 2004</b>		Group	
<b>U.S. PATENT DOCUMENTS</b>								
Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date if Appropriate	
<b>FOREIGN PATENT DOCUMENTS</b>								
		Document Number	Date	Country	Class	Subclass	Translation	
							Yes	No
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>								
	<b>34</b>	Partial European Search Report; for EP Application No. 01 99 7029; completed 12/21/2004						
	<b>35</b>	Partial European Search Report; for EP Application No. 06 01 6543.8; completed 10/4/2006						
	<b>36</b>	Supplemental European Search Report; for EP Application No. 02 80 5676; issued 2/7/2005						
	<b>37</b>	Baraldi, P.G. et al., (1999) "A1 and A3 adenosine receptor agonists: an overview." <i>Expert Opinion on Therapeutic Patents</i> , 9(5):515-527						
	<b>38</b>	Baraldi, P.G. (2003) "Recent developments in the field of A2A and A3 adenosine receptor antagonists" <i>Eur. J. Med. Chem.</i> 38(4) 367						
	<b>39</b>	Baraldi, P.G. et al., (1999) "A1 and A3 adenosine receptor agonists: an overview." <i>Expert Opinion on Therapeutic Patents</i> , 9(5):515-527						
	<b>40</b>	Baraldi, P.G. et al., (2004) "Allosteric modulators for the A1 adenosine receptor." <i>Expert Opinion on Therapeutic Patents</i> , 14(1):71-79						
	<b>41</b>	Borman, S. (2001) "A3 Receptors" <i>C&amp;EN</i> , 79(7), 37						
	<b>42</b>	Bremer et al. (2002) "Therapy of Crohn's Disease in Childhood", <i>Expert Opin. Pharmacother.</i> 3(7): 809-825						
	<b>43</b>	Christofi, F.L. et al. (2001), "Differential Gene Expression of Adenosine A1, A2a, A2b, and A3 Receptors in the Human Enteric Nervous System", <i>J. Comp. Neurol.</i> 439(1): 46-64						
	<b>44</b>	Corset, V. et al. (2000), "Netrin-1-mediated axon outgrowth and cAMP production requires interaction with adenosine A2b receptor", <i>Nature</i> , 407 (6805): 747-750						
	<b>45</b>	Dubey, R.K. et al. (2001), "A2B Receptors Mediate the Antimitogenic Effects of Adenosine in Cardiac Fibroblasts", <i>Hypertension</i> 37: 716-721						
	<b>46</b>	Faivre, K. et al., (2001) "Suppression of Cellular Invasion by Activated G-Protein Subunits Gao, Gai1, and Gai3 and Sequestration of Gβγ", <i>Mol. Pharmacol.</i> 60: 363-372						
	<b>47</b>	Feoktistov, I. and Biaggioni, I., (1997) "Adenosine A2B Receptors", <i>Pharmacol. Rev.</i> 49(4): 381-402						
	<b>48</b>	Feoktistov, I. et al., (2002) "Differential Expression of Adenosine Receptors in Human Endothelial Cells", <i>Circulation Research</i> 90: 531-538						
	<b>49</b>	Fishman P (2003) "Pharmacology and therapeutic applications of A3 receptor subtype" <i>Curr. Top. Med. Chem.</i> 3(4): 463-9						
	<b>50</b>	Gao, Z. et al., "A2B Adenosine and P2Y2 Receptors Stimulate Mitogen-activated Protein Kinase in Human Embryonic Kidney-293 Cells" <i>J. Bio. Chem.</i> (1999) 274(9): 5972-5980						
	<b>51</b>	Grant, M.B. et al., (2001) "Proliferation, Migration, and ERK Activation in Human Retinal Endothelial Cells through A2B Adenosine Receptor Stimulation", <i>Invest. Ophthalmol. Vis. Sci.</i> 42(9): 2068-2073						
	<b>52</b>	Guo, Y. et al., (2001) "Targeted deletion of A3 adenosine receptor confers resistance to myocardial ischemic injury and does not prevent early preconditioning." <i>J Mol Cell Cardiol</i> , 33:825-830						
	<b>53</b>	Haynes, J. Jr. et al., (1999) "5-(N-ethylcarboxamido) adenosine desensitizes the A2b-adenosine receptor in lung circulation", <i>Am. J. Physiol.</i> 276(6): H1877-H1883						
	<b>54</b>	Herndon, J.L. et al., (1992) Herndon, J.L. et al., "Ketanserin Analogs: Structure-Affinity Relationships for 5-HT2 and 5-HT1C Serotonin Receptor Binding", <i>J. Med. Chem.</i> 35(26): 4903-4910						
	<b>55</b>	Hoeschst India Ltd., India "Pharmacologically active pyrimido "[4,5-b]indoles and their salts." Database accession No. 106:84629 HCA XP002121648						
<b>EXAMINER</b>			<b>DATE CONSIDERED</b>					
<p><b>*EXAMINER:</b> Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>								

<b>Form PTO-1449</b>		<b>U.S. Department of Commerce Patent and Trademark Office</b>			Atty. Docket No. <b>60390-AZ-PCT-US/JPW/GJG/ML</b>		Serial No. <b>10/816,329</b>	
<b>INFORMATION DISCLOSURE CITATION</b> (Use several sheets if necessary)					Applicants: <b>Arlindo Castelhana et al.</b>			
					Filing Date <b>March 31, 2004</b>		Group	
<b>U.S. PATENT DOCUMENTS</b>								
Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date if Appropriate	
<b>FOREIGN PATENT DOCUMENTS</b>								
		Document Number	Date	Country	Class	Subclass	Translation	
							Yes	No
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>								
	56	Kiichiro, K. et al. "Synthesis of pyrazinecarboxylic acid derivs. - (II) derivs. of 3-aminopyrazinecarboxylic acid" Chem. Abstracts 56:8713						
	57	Kiritsy, J.A. et al., (1978) "Synthesis and Quantitative Structure-Activity Relationships of Some Antibacterial 3-Formylrifamycin SV N-(4-Substituted phenyl) piperazinoacethydrazones" J. Med. Chem. 21(12): 1301-1307						
	58	Klumpp, D.A. et al., (1999) "Synthesis of Aryl-Substituted Piperidines by Superacid Activation of Piperidones" J. Org. Chem. 64(18): 6702-6705						
	59	Linden, J. et al., (1998) "The Structure and Function of A1 and A2B Adenosine Receptors" Life Sciences 62(17-18): 1519-1524						
	60	Meade et al., PubMed Abstract (Life Sci. 69(11):1225-40) August 2001						
	61	Michell, C.H. (1999) "A3 adenosine receptors regulate Cl <sup>-</sup> channels of nonpigmented ciliary epithelial cells" Am. J. Physiol. 276: C659-C666						
	62	Mirabet, M. et al., (1999) "Expression of A2B adenosine receptors in human lymphocytes: their role in T cell activation" J. Cell. Sci. 112(4): 491-502						
	63	Mitchell, C.H. et al., "Adenosine A3 Receptor Activation Reduces Cell Volume and Activates Cl <sup>-</sup> Current in Human Ciliary Epithelial Cells", <i>FASEB J</i> , A134 (Abstract only)						
	64	Müller, C.E. (2001) "A3 Adenosine Receptor Antagonists" Mini Reviews in Med. Chem. 1(4): 339						
	65	Müller, C.E. et al., "Imidazo [2,1-i] purin-5-ones and Related Tricyclic Water-Soluble Purine Derivatives: Potent A2A- and A3-Adenosine Receptor Antagonists", (2002) J. Med. Chem. 45(16): 3440-3450						
	66	Nagarathnam, D. et al., (1998) "Design and Synthesis of Novel $\alpha$ 1a Adrenoceptor-Selective Dihydropyridine Antagonists for the Treatment of Benign Prostatic Hyperplasia", J. Med. Chem. 41(26): 5320-5333						
	67	Nyce J.W. (1997) "DNA Antisense thrapy for asthma in an animal model" 385: 721. Walker (1997) Am. J. Respir. Cell Mol. Biol. 161: 531						
	68	Polosa (2002) "Adenosine-receptor subtypes: their relevance to adenosine-mediated responses in asthma and chronic obstructive pulmonary disease", Eur. Respir. Journal 20,488-496						
	69	Priego, E.-M. et al., "Pyrido [2,1-f]purine-2,4-dione Derivatives as a Novel Class of Highly Potent Human A3 Adenosine Receptor Antagonists", (2002) J. Med. Chem., 45(16): 3337-3344						
	70	Ralevic, V. And Burnstock, G., (1998) "Receptors for Purines and Pyrimidines", Pharmacol. Rev. 50(3): 413-492						
	71	Regnauld, K. et al., (2002) "G-protein $\alpha$ olf subunit promotes cellular invasion, survival, and neuroendocrine differentiation in digestive and urogenital epithelial cells", Oncogene 21(25): 4020-4031						
	72	Robinson, "Medical Therapy of Inflammatory Bowel Disease for the 21st Century", Eur J Surg. Suppl 582:90-98, 1998						
	73	Simone, Oncology: Introduction Cecil Textbook of Medicine, 20th Edition, Vol. 1, pp. 1004-1010, 1996						
	74	Singh et al., "Immune therapy in inflammatory bowel disease and models of colitis", British Journal of Surgery, 88: 1558-1569, 2001						
	75	Tanaka, H. et al. "Preparation and formulation of fused pyrimidine compounds as CRF receptor antagonists." Database accession no. 129:109098 HCA XP002121647						
EXAMINER				DATE CONSIDERED				
<p><b>*EXAMINER:</b> Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>								

Form PTO-1449		U.S. Department of Commerce Patent and Trademark Office		Atty. Docket No. 60390-AZ-PCT-US/JPW/GJG/ML		Serial No. 10/816,329	
<b>INFORMATION DISCLOSURE CITATION</b> (Use several sheets if necessary)				Applicants: <b>Arlindo Castelhana et al.</b>			
				Filing Date <b>March 31, 2004</b>		Group	
<b>U.S. PATENT DOCUMENTS</b>							
Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date if Appropriate
<b>FOREIGN PATENT DOCUMENTS</b>							
		Document Number	Date	Country	Class	Subclass	Translation
							Yes    No
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>							
	76	Van Niel, M.B. et al., "Fluorination of 3-(3-(Piperidin-1-yl)propyl)indoles and 3-(3-(Piperazin-1-yl)propyl)indoles Gives Selective Human 5-HT <sub>1D</sub> Receptor Ligands with Improved Pharmacokinetic Profiles" <i>J. Med. Chem.</i> (1999) 42(12): 2087-2104					
	77	West, R.A. et al. (1961) "2-alkyl(aryl)-and 2,7-dimethyl-4-substituted aminopyrrolo[2,3-d]pyrimidines." <i>J. Org. Chem.</i> , 26:3809-3812					
	78	Yan, Luo et al. (2003) Expert Opinion on Emerging Drugs, vol. 8, no. 2 pp. 537-576					
EXAMINER				DATE CONSIDERED			
*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							